Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by First Trust Advisors LP

First Trust Advisors LP increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 62.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 406,057 shares of the medical equipment provider’s stock after purchasing an additional 156,388 shares during the period. First Trust Advisors LP owned 0.20% of Zimmer Biomet worth $39,997,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legacy Wealth Asset Management LLC grew its stake in Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after buying an additional 106 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 111 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the period. Generali Asset Management SPA SGR grew its position in shares of Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after acquiring an additional 122 shares during the last quarter. Finally, Brookstone Capital Management grew its position in shares of Zimmer Biomet by 1.3% during the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after acquiring an additional 123 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Sanford C. Bernstein raised their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Friday, January 9th. Finally, UBS Group reissued a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Trading Down 1.1%

Zimmer Biomet stock opened at $92.68 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock has a market capitalization of $18.13 billion, a PE ratio of 26.18, a price-to-earnings-growth ratio of 1.92 and a beta of 0.58. The firm has a 50 day simple moving average of $92.34 and a 200-day simple moving average of $95.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is currently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.